US opioid deaths have fallen to their lowest level in nearly a decade, the Department of Health and Human Services (HHS) announced on October 27, 2026, releasing new analysis that also puts America's overall death rate in 2025 at the lowest ever recorded. The announcement, made by HHS Secretary Robert F. Kennedy Jr. at an event at the Detroit Wayne Integrated Health Network in Detroit, Michigan, credits a decade of work to cut unnecessary opioid prescribing, disrupt the illicit fentanyl supply chain and expand treatment and recovery services.

The headline finding is stark: after more than 30 years in which opioid deaths rose almost without interruption, the toll has now dropped sharply from its peak. An independent analysis published days earlier put opioid overdose deaths at 44,564 in 2025, down from a peak of 81,806 in 2022 — a fall of almost half in three years. The HHS analysis adds the prescribing and treatment data behind that reversal: far fewer Americans are receiving prescription opioids than a decade ago, while far more are receiving medicines that treat opioid use disorder. For families who have lived through the epidemic, the numbers mark the first sustained good news in a generation — even as researchers caution that the crisis is far from over.

Key Points

• US opioid deaths are at their lowest since President Donald Trump declared a public health emergency in 2017, HHS announced on October 27, 2026.
• The overall age-adjusted death rate reached 689.2 deaths per 100,000 people in 2025, the lowest ever reported, according to provisional CDC data examined by HHS.
• Opioid prescriptions dispensed fell to 45.3% of their March 2015 level, and total opioid dosage dispensed fell to 35.2% of that baseline.
• Patients filling retail prescriptions for buprenorphine or naltrexone, medicines used to treat substance use disorders, rose to 218% of the March 2015 level.
• Independent researchers put opioid overdose deaths at 44,564 in 2025, down from a peak of 81,806 in 2022, but caution the decline began before the current administration's border measures.

What Happened

HHS released two linked pieces of work on October 27. The first is a report from the Office of the Assistant Secretary for Planning and Evaluation (ASPE), titled "The U.S. Age-Adjusted Death Rate Reached a Record Low in 2025: What Drove the Decline?", which examines the Centers for Disease Control and Prevention's provisional finding that the overall age-adjusted death rate reached 689.2 deaths per 100,000 people in 2025 — the lowest ever reported. The second is an article in Health Affairs Forefront, "Two Opioid Policy Trends Are Moving in the Right Direction: Sustaining a Decade of Progress", which tracks pharmacy dispensing from March 2015 through March 2026.

The dispensing figures tell a story of a prescribing culture transformed. Using population-adjusted measures, the researchers found that opioid prescriptions dispensed fell to 45.3% of their March 2015 level. Total opioid dosage dispensed fell even further, to 35.2% of the baseline, meaning that not only are fewer prescriptions being written, but the prescriptions that are written carry smaller doses. The number of patients receiving prescription opioids through retail pharmacies fell to 49.6% of the baseline — roughly half the patients of a decade ago.

At the same time, treatment has expanded sharply. The number of patients filling retail prescriptions for buprenorphine or naltrexone, the medicines used to treat substance use disorders, rose to 218% of the March 2015 level — more than double. That shift, from prescribing opioids to prescribing treatment for opioid dependence, is the central trend HHS points to in explaining why deaths are falling.

Secretary Kennedy announced the findings in Detroit, a city that has felt the epidemic acutely, at the Detroit Wayne Integrated Health Network. The choice of venue underlined the administration's message: the numbers are not abstractions, but the result of clinics, prescribers and recovery programmes working in communities where addiction has taken a heavy toll.

Background and Context

America's opioid epidemic unfolded in waves over more than three decades. It began in the 1990s with overdoses involving opioid painkillers, moved to heroin, and then — most lethally — to illicit fentanyl, a synthetic opioid many times more potent than heroin. By 2022, opioid overdose deaths peaked at 81,806, according to the analysis published in STAT on October 23, 2026. Overall drug overdose deaths peaked at nearly 110,000 in 2022, fell a little in 2023, then dropped 27% in 2024 to around 80,000 — the largest one-year decline ever recorded.

The policy response also has a long history. President Trump declared the opioid crisis a public health emergency in October 2017, when the overdose death rate stood at 21.9 per 100,000 people. During his first term, he signed the 2018 SUPPORT for Patients and Communities Act, strengthening the federal response through prevention, treatment and recovery programmes. His administration also pursued a plan to reduce nationwide opioid prescription fills by one-third within three years, and in 2018 the Justice Department and the Drug Enforcement Administration (DEA) proposed lowering 2019 manufacturing quotas for six frequently misused opioids by an average of 10%. Together, HHS says, those policies led to the first reduction in drug-related deaths in nearly three decades.

Since returning to office in 2025, Trump has renewed that agenda, according to HHS. The administration says it fully closed the Southern Border to illegal entry, signed the SUPPORT for Patients and Communities Reauthorization Act of 2025, continuing and updating programmes addressing substance use disorders, overdose prevention and recovery, and saw the DEA intensify efforts to disrupt the global fentanyl supply chain through its Fentanyl Free America initiative. In January 2026, Trump established the Great American Recovery, an effort to better align federal programmes and integrate prevention, treatment, recovery support and re-entry across systems.

The broader overdose picture supports the direction of travel, even if the details are contested. Federal data released in October 2026 showed an estimated 73,000 people died from overdoses in the 12-month period ending in August 2025, down about 21% from 92,000 in the previous 12-month period. Deaths were down in all states except Arizona, Hawaii, Kansas, New Mexico and North Dakota, according to CDC officials cited in that reporting. In Texas, fentanyl-related deaths fell 46% since 2023, from 2,307 deaths to 1,254 deaths in 2025, according to the Texas Department of State Health Services. But the same federal update warned that the decline was slowing, and that the monthly death toll was still not back to what it was before the COVID-19 pandemic, let alone before the current epidemic began.

Opioid Deaths Lowest in Nearly a Decade: What the Numbers Show

The claim that opioid deaths are at their lowest in nearly a decade rests on two different kinds of evidence, and it is worth separating them. The first is the prescribing and treatment data from the Health Affairs Forefront analysis, which covers March 2015 to March 2026 and shows a sustained, decade-long change in how America uses opioids. Prescriptions halved, doses fell by nearly two-thirds, and treatment medicines more than doubled. Those are structural changes, not a single good year, and they are the strongest evidence that something fundamental has shifted.

The second is the death data itself. The ASPE report's headline — an overall age-adjusted death rate of 689.2 per 100,000 in 2025, the lowest ever reported — covers all causes of death, not opioids alone, and HHS presents it as evidence that the opioid decline is large enough to move the national mortality rate. The opioid-specific figures come from the STAT analysis: 81,806 opioid overdose deaths in 2022, falling to 44,564 in 2025. That is a fall of about 45%, and it helped push US life expectancy to a record high in 2024.

What the numbers do not show is a crisis ended. Even at 44,564 opioid overdose deaths, the annual toll remains roughly double the rates seen before illicit fentanyl flooded the drug supply a decade ago. The monthly death toll is still above pre-pandemic levels. And the decline itself is slowing, according to the latest CDC provisional data. The fairest reading of the HHS announcement is therefore not "mission accomplished" but "a historic reversal, still incomplete" — a framing that both the administration's critics and many public health researchers would accept.

Reactions and Quotes

Secretary Kennedy framed the findings as the result of a deliberate, multi-front strategy. "President Trump has attacked the opioid crisis from every direction — rightsizing opioid prescribing, disrupting the fentanyl supply chain, and expanding treatment and recovery," he said. "Those actions are saving lives and driving opioid deaths to the lowest in nearly a decade. We will keep pressing forward until every American struggling with addiction has a real path to recovery and a chance to rebuild a healthy life."

Kathryn Burgum, HHS Senior Advisor and co-chair of the Great American Recovery, struck a more personal note. "For families living with addiction, saving a life means another birthday, another holiday together, another chance to come home — that is what President Trump's commitment to this fight is about," she said. "Through the President's Great American Recovery, we will keep our focus on the people behind the numbers and the families counting on the Trump Administration to save more American lives."

Not everyone accepts the administration's explanation for the decline. In their October 23 STAT analysis, researchers J. Travis Donahoe of the University of Pittsburgh, David T. Zhu of Virginia Commonwealth University and Michael L. Barnett of Brown University argue that neither of the two most popular explanations fits the timing or scale of the drop. Deaths began falling in mid-2023, they note, months before President Trump's inauguration and the subsequent border crackdown, so the border measures cannot explain the start of the decline. Nor, they argue, can naloxone saturation: in a paper published in JAMA, they found that emergency medical services administration and layperson administration of naloxone have declined since mid-2023, even as deaths fell. Improved treatment access is also not a sufficient explanation on its own, they write, because evidence-based treatment with medicines has increased steadily and incrementally, not by the order of magnitude needed to explain such a large and sudden drop.

That scepticism does not dispute that deaths are falling — the researchers call it one of the biggest public health reversals in decades — but it does dispute why. Their analysis leaves open the possibility of a supply shock or market disruption in the illicit fentanyl supply, a theory other epidemiologists have also raised: if the fentanyl supply became less predictable or was temporarily displaced by less lethal substances, deaths could fall sharply without any single policy change explaining it. The honest answer, for now, is that several forces are probably at work at once, and disentangling them will take more years of data.

Why It Matters

The opioid decline matters first because of its sheer scale. A fall from 81,806 opioid overdose deaths to 44,564 in three years means roughly 37,000 fewer deaths in a single year than at the peak — tens of thousands of people alive who, on the old trajectory, would not be. That is why the overall age-adjusted death rate hit a record low in 2025, and why US life expectancy reached a record high in 2024. Few public health reversals of this size have ever been recorded in the United States.

It matters second because it tests a long-running policy debate. For years, critics argued that cutting prescriptions would simply push people toward illicit fentanyl, making things worse. The new data suggest the opposite happened over the long run: prescriptions halved, treatment more than doubled, and deaths fell by nearly half. That does not settle the debate — the transition years were brutal, and illicit fentanyl still kills tens of thousands a year — but it does shift the burden of proof toward those who argue that prescribing restraint cannot work.

It matters third because the politics of the epidemic are now contested in a new way. With deaths falling, both the administration and its critics want credit for, or at least an explanation of, the reversal. How that argument resolves will shape funding for treatment, naloxone distribution, border enforcement and recovery programmes for years. If the decline is attributed mainly to enforcement, enforcement budgets grow. If it is attributed mainly to treatment and harm reduction, those budgets grow instead. The data so far support both stories in part, which is why the argument is unlikely to end soon.

Finally, it matters because the work is unfinished. At 44,564 opioid deaths a year, the United States is still losing more than 120 people a day to opioid overdoses. The decline is slowing. Fentanyl remains in the drug supply, and new synthetic opioids continue to appear. The HHS announcement is best read as a milestone on a long road, not a destination.

What Happens Next

The immediate next step is more data. The ASPE report and the Health Affairs Forefront analysis will be scrutinised by researchers, and the CDC's provisional monthly overdose figures will show whether the decline continues through late 2025 and into 2026, or whether the slowing trend identified in the October data hardens into a plateau. State-level figures will matter too: the five states where deaths did not fall in the latest 12-month period — Arizona, Hawaii, Kansas, New Mexico and North Dakota — will be watched for signs of a localised resurgence.

On the policy side, the Great American Recovery initiative, established in January 2026, is the administration's vehicle for the next phase: aligning federal programmes and integrating prevention, treatment, recovery support and re-entry. Whether it delivers new funding, new treatment capacity or mainly coordination will become clearer as its programmes roll out. The SUPPORT for Patients and Communities Reauthorization Act of 2025 will also shape what states and clinics can actually offer, since it continues and updates the programmes that fund much of the country's treatment infrastructure.

For families and communities, the practical message is unchanged and urgent: naloxone, the overdose-reversal medicine, remains a critical, lifesaving tool that reverses tens of thousands of overdoses a year, even if its distribution alone does not explain the national decline. Treatment with buprenorphine and methadone remains the gold-standard medical care for opioid use disorder. And the expansion of those treatments — more than doubling over the decade — is the trend that, whatever else explains the death decline, gives the most people a path back.

The longer question is whether America can sustain the reversal. Past drug epidemics have shown that declines can reverse when attention moves on, funding dries up or the drug supply changes. The HHS announcement is a moment to recognise genuine progress — and to ask, with the researchers who studied it most closely, what actually caused it, so that the policies that worked can be kept and the ones that did not can be dropped.

Frequently Asked Questions

How low have US opioid deaths fallen?

HHS says opioid-related deaths are at their lowest since President Trump declared a public health emergency in 2017. Independent researchers put opioid overdose deaths at 44,564 in 2025, down from a peak of 81,806 in 2022.

What is the overall US death rate in 2025?

According to provisional CDC data examined in the ASPE report, the overall age-adjusted death rate reached 689.2 deaths per 100,000 people in 2025, the lowest ever reported.

How much has opioid prescribing fallen?

From March 2015 to March 2026, opioid prescriptions dispensed fell to 45.3% of their baseline level, total opioid dosage dispensed fell to 35.2%, and patients receiving prescription opioids fell to 49.6%. Patients filling prescriptions for buprenorphine or naltrexone rose to 218% of baseline.

Why do some researchers dispute the administration's explanation?

Deaths began falling in mid-2023, before the current administration's border measures, and naloxone administration has declined since mid-2023, so neither factor alone fits the timing. Researchers say several forces, possibly including a shift in the illicit fentanyl supply, are likely at work.

Is the opioid crisis over?

No. More than 44,000 Americans still died of opioid overdoses in 2025, the decline is slowing, and the monthly toll remains above pre-pandemic levels. The crisis has receded, but it has not ended.

Related coverage on US News Pulse: Darwin's cat food Salmonella alert: FDA warns two lots after cat hospitalised and Blood pressure drug recall: 21,620 bottles pulled over too much telmisartan.